Arlington Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-20,417
| Closed | -$2.56M | – | 58 |
|
|
2025
Q2 | $2.56M | Sell |
20,417
-7,308
| -26% | -$911K | 0.95% | 54 |
|
|
2025
Q1 | $3.79M | Buy |
+27,725
| New | +$3.96M | 1.49% | 44 |
|
|
2024
Q4 | – | Sell |
-19,214
| Closed | -$3.72M | – | 59 |
|
|
2024
Q3 | $3.72M | Buy |
19,214
+4,902
| +34% | +$1.03M | 1.46% | 53 |
|
|
2024
Q2 | $3.32M | Buy |
14,312
+1,823
| +15% | +$396K | 1.65% | 14 |
|
|
2024
Q1 | $2.69M | Buy |
12,489
+833
| +7% | +$195K | 1.37% | 52 |
|
|
2023
Q4 | $3.02M | Buy |
+11,656
| New | +$2.86M | 0.87% | 39 |
|
|
2023
Q3 | – | Sell |
-5,025
| Closed | -$1.43M | – | 378 |
|
|
2023
Q2 | $1.43M | Sell |
5,025
-50
| -1% | -$14.9K | 0.22% | 45 |
|
|
2023
Q1 | $1.41M | Sell |
5,075
-204
| -4% | -$56.4K | 0.2% | 41 |
|
|
2022
Q4 | $1.46M | Sell |
5,279
-1,356
| -20% | -$383K | 0.23% | 40 |
|
|
2022
Q3 | $1.77M | Buy |
6,635
+116
| +2% | +$24.6K | 0.71% | 31 |
|
|
2022
Q2 | $1.33M | Sell |
6,519
-985
| -13% | -$201K | 0.44% | 41 |
|
|
2022
Q1 | $1.58M | Sell |
7,504
-1,486
| -17% | -$323K | 0.45% | 42 |
|
|
2021
Q4 | $2.16M | Buy |
8,990
+232
| +3% | +$59.7K | 0.58% | 38 |
|
|
2021
Q3 | $2.48M | Buy |
8,758
+488
| +6% | +$160K | 0.71% | 32 |
|
|
2021
Q2 | $2.86M | Sell |
8,270
-43
| -0.5% | -$13K | 0.99% | 20 |
|
|
2021
Q1 | $2.33M | Buy |
8,313
+753
| +10% | +$203K | 0.85% | 26 |
|
|
2020
Q4 | $1.85M | Buy |
7,560
+13
| +0.2% | +$3.35K | 0.85% | 28 |
|
|
2020
Q3 | $2.14M | Hold |
7,547
| – | – | 1.17% | 20 |
|
|
2020
Q2 | $2.02M | Buy |
7,547
+630
| +9% | +$189K | 1.13% | 20 |
|
|
2020
Q1 | $2.19M | Buy |
6,917
+5,452
| +372% | +$1.65M | 1.14% | 20 |
|
|
2019
Q4 | $435K | Buy |
1,465
+330
| +29% | +$91.6K | 0.27% | 33 |
|
|
2019
Q3 | $264K | Sell |
1,135
-7,011
| -86% | -$1.63M | 0.17% | 44 |
|
|
2019
Q2 | $1.91M | Buy |
8,146
+7,631
| +1,482% | +$1.76M | 0.85% | 30 |
|
|
2019
Q1 | $122K | Sell |
515
-1,895
| -79% | -$597K | 0.09% | 89 |
|
|
2018
Q4 | $725K | Buy |
2,410
+120
| +5% | +$38.3K | 0.47% | 40 |
|
|
2018
Q3 | $809K | Buy |
2,290
+25
| +1% | +$8.61K | 0.57% | 37 |
|
|
2018
Q2 | $657K | Hold |
2,265
| – | – | 0.62% | 40 |
|
|
2018
Q1 | $620K | Buy |
2,265
+225
| +11% | +$69.8K | 0.58% | 39 |
|
|
2017
Q4 | $650K | Buy |
+2,040
| New | +$654K | 0.67% | 39 |
|
Other funds holding BIIB
Arlington Partners's BIIB Position: Q3 2025 in Review
Arlington Partners sold out of Biogen (BIIB) in Q3 2025, closing a stake of 20,417 shares — an estimated $2.56M sold.
Arlington Partners first reported a position in BIIB in Q4 2017 and held it in 29 quarters. The position peaked at $3.79M in Q1 2025. 905 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.
- Arlington Partners reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
- Arlington Partners sold 20,417 Biogen shares in Q3 2025, an estimated $2.56M.
- Arlington Partners first reported a position in Biogen in Q4 2017 and held it in 29 quarters.
- Arlington Partners's Biogen position peaked at $3.79M in Q1 2025.
- 905 funds tracked by Wall St. Rank held Biogen as of Q3 2025.
Based on Arlington Partners's 13F filing for Q3 2025, filed 28 Oct 2025.